June 21, 2025

European leaders worry they’re too reliant on U.S. tech

European governments may be reconsidering their use of American technology and services, according to a new report in The New York Times.

December 2023

Jagat, a location-based social network that focuses on real-life connections, surpasses 10M users

December 15, 2023

Jagat, a social network that is designed to get you out more with your friends instead of mindlessly scrolling on your phone, has surpassed 10 million users globally. The location-based social network, which launched earlier this year in March, wants to help people focus on real-life connections and make friends. The app is essentially a […]

© 2023 TechCrunch. All rights reserved. For personal use only.

Why these 30 web3 founders are optimistic about 2024

December 15, 2023

About 70% of founders are optimistic about the opportunities for crypto startups in 2024, per a new survey shared exclusively with TechCrunch+.

© 2023 TechCrunch. All rights reserved. For personal use only.

The Download: beyond CRISPR, and OpenAI’s superalignment findings

December 15, 2023
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Vertex developed a CRISPR cure. It’s already on the hunt for something better. The company that just got approval to sell the first gene-editing treatment in history, for sickle-cell disease, is already looking…

In the fight against Methane, a key GHG, Valley investors have hit upon an unusual target: Cow burps

December 15, 2023

What do iconic Valley investors Zachary Bogue and Chris Sacca have in common? They are both trying to stop cows from burping methane. No, really. And a Sacca investment just raised $20 million to do just that. What gives? With the conclusion of COP28, the global talks on the climate crisis, Methane is going up […]

© 2023 TechCrunch. All rights reserved. For personal use only.

Vertex developed a CRISPR cure. It’s already on the hunt for something better.

December 15, 2023
The company that just got approval to sell the first gene-editing treatment in history, for sickle-cell disease, is already looking for an ordinary drug that could take its place. Vertex Pharmaceuticals has a 50-person team working “to make a pill that doesn’t do gene editing at all,” says David Altshuler, head of research at the…